A number one automation company powering life sciences labs, has raised $40m to speed up its rapid growth and industry presence across the US, UK and EMEA.

Scientific organizations are increasingly focused on the speed and adaptability of their experimentation and data collection. This is occurring concurrently they struggle to seek out laboratory real estate in addition to finding and retaining expert lab staff. This convergence is resulting in organisations rethinking their tooling, data infrastructure and skill to experiment at scale.

Automata’s LINQ automation platform is designed to make automation easily adoptable by science labs across research institutions, hospital groups and pharmaceutical and biotech corporations and CROs, whether or not they are running high throughput workflows or experimenting with a high rate of workflow changeover requiring dynamic protocol development.

Dimension led the round with participation from A.P. Moller Holding, parent company of the A.P. Moller Group and owners of, amongst other businesses, laboratory testing group Unilabs. They’ve invested alongside returning investors, Octopus Ventures, Hummingbird, Isomer Capital, Possible Ventures and Aldea Ventures.

The proceeds might be used to fund Automata’s geographic and team expansion plans, focusing the business on the fast-growing opportunities in the worldwide life sciences sector and developing its brand recognition and presence within the industry.

This latest funding round builds on the success of the $50m Series B round raised in January 2022 which enabled the team to deliver on its initial commercialisation and expansion plans, specifically its deployment footprint in Europe and the UK and rapid growth within the US. For the reason that last funding round in January 2022, Automata has seen 150% revenue growth. It has also seen a 12-times increase in live system hours in customer-deployed systems.

Current customers include NHS Trusts resembling The Royal Marsden NHS Foundation Trust, academic institutions including The Francis Crick Institute, testing labs resembling HSL, CDMOs and CROs, pharma and biotech corporations, resembling Astra Zeneca and bit.bio.

“The last two years have been hugely exciting at Automata as we’ve seen LINQ increase the dimensions of customer workflows in addition to meaningfully increasing their ability to generate top quality data – accelerating their pace of discovery and experimentation.”

Mostafa Elsayed, Founder and CEO of Automat

He added, “Achieving a fundraise with exciting and experienced investors in a fairly difficult funding environment is an actual endorsement of the potential and capabilities of our lab automation platform and the work the team has achieved.”

He also added, “The raise enables us to proceed to concentrate on our existing and upcoming deployments in addition to continuing to develop products that transform how scientists interact with their labs. Most significantly, it should help us to speed up the impact our users are already having on people’s lives around the globe.”

The raise enables us to proceed to concentrate on our existing and upcoming deployments in addition to continuing to develop products that transform how scientists interact with their labs. Most significantly, it should help us to speed up the impact our users are already having on people’s lives around the globe.”

Mostafa Elsayed, Founder and CEO of Automata

“The fashionable lab is a knowledge factory, requiring precise coordination across a collection of lab instruments juggling multiple protocol runs. In consequence, the industry needs a lab automation system that’s built with an emphasis on speed, reliability, reconfigurability, reproducibility, and scale. Automata’s modular software and hardware LINQ system delivers just that and we’re thrilled to partner with them to construct a category-defining business on this space.”

Nan Li, Co-Founder and Managing Partner of Dimension

“We’re delighted to partner with Automata, an emerging leader in modernizing and automating the worldwide life science industry. Automata’s solutions help increase throughput, lower cost, and speed up innovation allowing its customers to concentrate on pushing further into leading edge medical and life science research.”

Chetan Mehta, Head of Growth Equity of A.P. Moller Holding